Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Faculty Medicine Year: 2025
Type of Publication: ZU Hosted Pages:
Authors:
Journal: The Lancet Public Health Elsevier Volume: 3
Keywords : Global, regional, , national burden , epilepsy, 1990–2021:    
Abstract:
Background Epilepsy is one of the most common serious neurological disorders and affects individuals of all ages across the globe. The aim of this study is to provide estimates of the epilepsy burden on the global, regional, and national levels for 1990–2021. Methods Using well established Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) methodology, we quantified the prevalence of active idiopathic (epilepsy of genetic or unknown origin) and secondary epilepsy (epilepsy due to an underlying abnormality of the brain structure or chemistry), as well as incidence, death, and disability-adjusted life-years (DALYs) by age, sex, and location (globally, 21 GBD regions and seven super-regions, World Bank country income levels, Socio-demographic Index [SDI], and 204 countries) and their trends from 1990 to 2021. Vital registrations and verbal autopsies provided information about deaths, and data on the prevalence and severity of epilepsy, largely came from population representative surveys. All estimates were calculated with 95% uncertainty intervals (UIs). Findings In 2021, there were 51·7 million (95% UI 44·9–58·9) people with epilepsy (idiopathic and secondary combined) globally, with an age-standardised prevalence of 658 per 100 000 (569–748). Idiopathic epilepsy had an age-standardised prevalence of 307 per 100 000 (235–389) globally, with 24·2 million (18·5–30·7) prevalent cases, and secondary epilepsy had a global age-standardised prevalence of 350 per 100 000 (322–380). In 2021, 0·7% of the population had active epilepsy (0·3% attributed to idiopathic epilepsy and 0·4% to secondary epilepsy), and the age-standardised global prevalence of epilepsy from idiopathic and secondary epilepsy combined increased from 1990 to 2021 by 10·8% (1·1–21·3), mainly due to corresponding changes in secondary epilepsy. However, age-standardised death and DALY rates of idiopathic epilepsy reduced from 1990 to 2021 (decline of 15·8% [8·8–22·8] and 14·5% [4·2–24·2], respectively). There were three-fold to four-fold geographical differences in the burden of active idiopathic epilepsy, with the bulk of the burden residing in low-income to middle-income countries: 82·1% (81·1–83·4) of incident, 80·4% prevalent (79·7–82·7), 84·7% (83·7–85·1) fatal epilepsy, and 87·9% (86·2–89·2) epilepsy DALYs. Interpretation Although the global trends in idiopathic epilepsy deaths and DALY rates have improved in the preceding decades, in 2021 there were almost 52 million people with active epilepsy (24 million from idiopathic epilepsy and 28 million from secondary epilepsy), with the bulk of the burden (>80%) residing in low-income to middle-income countries. Better treatment and prevention of epilepsy are required, along with further research on risk factors of idiopathic epilepsy, good-quality long-term epilepsy surveillance studies, and exploration of the possible effect of stigma and cultural differences in seeking medical attention for epilepsy.
   
     
 
       

Author Related Publications

  • Aly Mohamed Abdelrahman Saad, "The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe The Euro Heart Survey on diabetes and the heart", Elsevier, 2004 More
  • Aly Mohamed Abdelrahman Saad, "Treatment and Health Status in Patients with Proven Coronary Artery Disease, but Ineligible for Revascularization. A Report from the Euro Heart Survey on Revascularization", Sage, 2006 More
  • Aly Mohamed Abdelrahman Saad, "Pharmacological treatment and perceived health status during 1-year follow up in patients diagnosed with coronary artery disease, but ineligible for revascularization: Results from the Euro Heart Survey on coronary revascularization", Sage, 2006 More
  • Aly Mohamed Abdelrahman Saad, "A 1-year follow up in patients diagnosed with coronary artery disease, but ineligible for revascularization. Results from The Euro Heart Survey on Coronary Revascularization", Oxford University Press, 2006 More
  • Aly Mohamed Abdelrahman Saad, "Atrial fibrillation management: a prospective survey in ESC Member Countries", Oxford University Press, 2005 More

Department Related Publications

  • Ahmed Shafea Mahmoud Morsy, "قيمه سمك الطانه والطبقة الوسطي للشريان السباتي والفخذي كعامل غير نافذ للتنبؤ بمرض الشريان التاجي", مجلة القلب المصرية, 2001 More
  • Ahmed Shafea Mahmoud Morsy, "تاثير توسيع الصمام الميترالي بالقسطره البالونية علي الارتجاع الوظيفي للصمام ثلاثي الشرفات وارتفاع ضغط الشريان الرئوي", مجلة جامعة الزقازيق الطبية, 2000 More
  • Tarek Abdelmoniem Abdelaziz, "Human C-reactive protein gene polymorphism andmetabolic syndrome are associated with premature coronary artery disease", Elsevier, 2013 More
  • Tarek Abdelmoniem Abdelaziz, "Synergistic Effect Between Lipoprotein Lipase and Apolipoprotein C3 Genes in Determining the Severity of Coronary Artery Disease", Springer, 2013 More
  • Eslam Alsayed Mohamed Mohamed Shehata, "Mitral annulus time intervals for assessment of left ventricular systolic function in ischemic cardiomyopathy", European Journal of Heart Failure Supplements (2012) 11, S128–S177, 2012 More
Tweet